GTC Biotherapeutics Receives NASDAQ Notice; Intends to Request Hearing

• Press Release
• Source: GTC Biotherapeutics, Inc.
• On 8:30 am EDT, Friday September 18, 2009

FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc.’s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the “Staff Determination”) on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the “Panel”), the Company’s securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2). The Staff Determination followed earlier correspondence from NASDAQ, which was announced by the Company on June 19, 2009.

Related Quotes

Symbol	Price	Change
GTCB	1.00	0.00

{"s" : "gtcb","k" : "c10,l10,p20,t10","o" : "","j" : ""}

GTC intends to request a hearing before the Panel, which will defer any action with respect to the Staff Determination until the Panel renders a decision following the hearing. The Company’s securities will continue to trade on The NASDAQ Capital Market in the interim. The Panel has discretion to grant an extension not to exceed 180 days from the date of the Staff notification. However, there can be no assurance that any such extension will be granted or that following the hearing the Panel will grant GTC’s request for continued listing.

About GTC Biotherapeutics, Inc.

GTC Biotherapeutics develops, supplies and commercializes therapeutic proteins produced through transgenic animal technology. ATryn^®, GTC’s recombinant human antithrombin, has been approved for use in the United States and Europe. ATryn is the first and only product produced in transgenic animals to be approved for therapeutic use anywhere in the world. In addition to ATryn, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa and IX, which are being developed for the treatment of hemophilia. GTC is also developing a portfolio of follow-on biologic monoclonal antibodies and a CD20 antibody with enhanced ADCC (antibody-dependent cell-mediated cytotoxicity). GTC’s intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC’s transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the substance or timing of any hearing or decisions by Nasdaq regarding GTC’s continued listing on the NASDAQ Capital Market. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports filed with the Securities and Exchange Commission, including the risks and uncertainties associated with dependence upon the actions of Nasdaq. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.

GTC Biotherapeutics, Inc.
Thomas E. Newberry, 508-370-5374
Vice President, Corporate Communications and Government Relations
tom.newberry@gtc-bio.com